Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Biomarker phenotype BEFREE Acetaminophen Responsive miR-19b Modulates SIRT1/Nrf2 Signaling Pathway in Drug-Induced Hepatotoxicity. 31077331 2019
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Biomarker phenotype BEFREE Underpinned by our comprehensive analysis, activation of the NRF2 network is one of several mechanism-based components that can be incorporated into holistic systems toxicology models to improve mechanistic understanding and preclinical prediction of DILI in man. 30426165 2019
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Therapeutic phenotype CTD_human Nrf2 Activation Ameliorates Hepatotoxicity Induced by a Heme Synthesis Inhibitor. 30215777 2019
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Biomarker phenotype BEFREE Bile acid transporters and the nuclear factor erythroid 2-related factor (Nrf-2)-mediated adaptive response play important roles in the development of drug-induced liver injury (DILI). 28688954 2017
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Therapeutic phenotype CTD_human P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2. 26958860 2016
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Biomarker phenotype BEFREE These data indicate that both Nrf2 and NF-κB signaling may be pivotal in the regulation of DILI. 26026609 2016
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Biomarker phenotype BEFREE Transcriptomics of the cell injury stress response pathways initiated by two hepatoxicants, diclofenac and carbamazepine, revealed the endoplasmic reticulum (ER) stress/translational initiation signaling and nuclear factor-erythroid 2 (NF-E2)-related factor 2 (Nrf2) antioxidant signaling as two major affected pathways, which was similar to that observed for the majority of ∼80 DILI compounds in primary human hepatocytes. 24752500 2014
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Therapeutic phenotype CTD_human Nrf2 protects against furosemide-induced hepatotoxicity. 24813929 2014
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Therapeutic phenotype CTD_human Role of Nrf2 in preventing ethanol-induced oxidative stress and lipid accumulation. 22627062 2012
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Therapeutic phenotype CTD_human Liver-specific loss of Atg5 causes persistent activation of Nrf2 and protects against acetaminophen-induced liver injury. 22491424 2012
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Biomarker phenotype BEFREE We have demonstrated previously that acetaminophen activates Nrf2 in mouse liver following administration of non-hepatotoxic and hepatotoxic doses in vivo, implying that Nrf2 may have an important role in the protection against drug-induced liver injury. 18785192 2008